NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm and TME Research, a cancer physician network, announced today that they have signed a deal to launch a precision medicine breast cancer registry.
Under the arrangement, the so-called Paradigm Neoadjuvant Breast Registry will use Paradigm's PCDx next-generation sequencing-based test and other technologies to characterize the genomes and profile the tumors of invasive breast cancer patients with the goal of identifying the best pre-surgical treatment for each individual.
According to the companies, the deal will start with a six-month pilot study that aims to enroll 100 patients across eight US centers, but could expand to 1,000 patients at 50 centers across the US.
"Not only do we anticipate patients enrolled in Paradigm's Neoadjuvant Breast Registry to benefit from tailored therapeutics, but we also aim to accelerate the pace of discovery in cancer genomics to move beyond the archaic one-size-fits-all approach to cancer treatment," Paradigm CEO Robert Penny said in a statement. "Determining if next-generation sequencing and other technologies assist in the selection of clinical trials and targeted treatments for patients being treated in the neoadjuvant setting with improved key clinical endpoints will be a first."